Stock listing
NASDAQ:IMMP Immutep Ltd Stock
US listing (NASDAQ) of Immutep Ltd · home listing ASX:IMM
Follow Immutep Ltd into a list and get an email when it puts out news.
Share price · NASDAQ:IMMP
$3.11 USD -0.31 (-9.1%)
Close on Nov 20, 2026
- Day range
- $3.09 – $3.41 USDNov 20, 2026
- Volume
- 44,784 sharesNov 20, 2026
- Market cap
- $22.92M USDAt the close on Nov 20, 2026 · price × 7.37M shares outstanding
- 52-week range
- $2.66 – $70.60 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $44,938 USDMedian day 7,739 shares · last 3 months, Aug 20, 2026 – Nov 6, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| ASX:IMM · Home | $0.024 AUD | +0.001 (+4.3%) | 2,376,037 | $0.025 | $0.026 | $0.024 | $0.023 | Close on Nov 20, 2026 |
| NASDAQ:IMMP | $3.11 USD | -0.31 (-9.1%) | 44,784 | $3.41 | $3.41 | $3.093 | $3.42 | Close on Nov 20, 2026 |
| OTC:PRRUF | $0.02 USD | 0.00 (0.0%) | — | $0.02 | $0.02 | $0.02 | $0.02 | Close on Nov 6, 2026 |
| Frankfurt:YP1B | €0.014 EUR | +0.002 (+16.7%) | 73,006 | €0.014 | €0.014 | €0.014 | €0.012 | Close on Nov 19, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 6, 2026 · NASDAQ:IMMP · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $3.34 | +0.65 | +24.2% | $2.69 | $3.49 | $2.69 | 97,169 | |
| $2.69 | -0.26 | -8.8% | $2.95 | $2.995 | $2.66 | 16,710 | |
| $2.95 | -0.045 | -1.5% | $3.01 | $3.035 | $2.93 | 5,450 | |
| $2.995 | -0.075 | -2.4% | $3.03 | $3.12 | $2.985 | 12,173 | |
| $3.07 | +0.01 | +0.3% | $3.10 | $3.111 | $3.00 | 11,625 | |
| $3.06 | -0.27 | -8.1% | $3.30 | $3.30 | $3.05 | 10,591 | |
| $3.33 | +0.01 | +0.3% | $3.04 | $3.55 | $3.04 | 14,038 | |
| $3.32 | +0.17 | +5.4% | $3.19 | $3.46 | $3.19 | 29,526 | |
| $3.15 | +0.05 | +1.6% | $3.10 | $3.30 | $3.10 | 13,557 | |
| $3.10 | -0.10 | -3.1% | $3.28 | $3.28 | $3.05 | 26,998 | |
| $3.20 | +0.03 | +0.9% | $3.21 | $3.23 | $3.10 | 7,942 | |
| $3.17 | -0.11 | -3.4% | $3.27 | $3.27 | $3.073 | 7,536 | |
| $3.28 | +0.02 | +0.6% | $3.22 | $3.395 | $3.21 | 9,209 | |
| $3.26 | +0.09 | +2.8% | $3.15 | $3.42 | $3.15 | 16,369 | |
| $3.17 | -0.03 | -0.9% | $3.29 | $3.29 | $3.13 | 6,783 | |
| $3.20 | -0.01 | -0.3% | $3.27 | $3.27 | $3.18 | 11,868 | |
| $3.21 | -0.17 | -5.0% | $3.31 | $3.31 | $3.06 | 19,070 | |
| $3.38 | -0.19 | -5.3% | $3.48 | $3.54 | $3.36 | 38,702 | |
| $3.57 | -0.10 | -2.7% | $3.60 | $3.70 | $3.437 | 26,994 | |
| $3.67 | +0.04 | +1.1% | $3.57 | $3.70 | $3.56 | 18,623 | |
| $3.63 | -0.21 | -5.5% | $3.785 | $3.785 | $3.55 | 23,406 | |
| $3.84 | -0.22 | -5.4% | $4.02 | $4.104 | $3.80 | 14,904 | |
| $4.06 | -0.28 | -6.5% | $4.28 | $4.31 | $4.04 | 9,611 | |
| $4.34 | +0.07 | +1.6% | $4.34 | $4.51 | $4.30 | 11,617 | |
| $4.27 | -0.08 | -1.8% | $4.35 | $4.50 | $4.18 | 25,192 | |
| $4.35 | -0.19 | -4.2% | $4.61 | $4.61 | $4.165 | 48,662 | |
| $4.54 | -0.11 | -2.4% | $4.70 | $4.70 | $4.53 | 11,135 | |
| $4.65 | -0.06 | -1.3% | $4.79 | $4.79 | $4.62 | 10,502 | |
| $4.71 | -0.17 | -3.5% | $4.87 | $4.87 | $4.60 | 34,041 | |
| $4.88 | -0.39 | -7.4% | $5.36 | $5.36 | $4.67 | 49,146 | |
| $5.27 | +0.03 | +0.6% | $5.56 | $5.56 | $5.122 | 1,663 | |
| $5.24 | -0.082 | -1.5% | $5.38 | $5.38 | $5.13 | 603 | |
| $5.322 | -0.34 | -6.0% | $5.70 | $5.70 | $5.252 | 1,879 | |
| $5.662 | -0.164 | -2.8% | $5.916 | $5.916 | $5.602 | 374 | |
| $5.826 | +0.072 | +1.3% | $5.62 | $5.938 | $5.602 | 894 | |
| $5.754 | -0.584 | -9.2% | $6.208 | $6.208 | $5.60 | 1,441 | |
| $6.338 | -0.202 | -3.1% | $6.52 | $6.642 | $6.30 | 613 | |
| $6.54 | -0.066 | -1.0% | $6.756 | $6.756 | $6.282 | 642 | |
| $6.606 | -0.016 | -0.2% | $6.796 | $6.796 | $6.582 | 921 | |
| $6.622 | -0.844 | -11.3% | $6.836 | $6.98 | $6.462 | 1,273 | |
| $7.466 | +0.964 | +14.8% | $7.35 | $8.10 | $7.10 | 8,018 | |
| $6.502 | -0.60 | -8.4% | $7.10 | $7.10 | $6.50 | 378 | |
| $7.102 | -0.194 | -2.7% | $7.40 | $7.40 | $7.10 | 269 | |
| $7.296 | -0.002 | 0.0% | $7.18 | $7.408 | $7.00 | 674 | |
| $7.298 | -0.004 | -0.1% | $7.598 | $7.598 | $7.208 | 156 | |
| $7.302 | -0.356 | -4.6% | $7.54 | $7.62 | $7.20 | 332 | |
| $7.658 | +0.234 | +3.2% | $7.54 | $7.70 | $7.41 | 296 | |
| $7.424 | +0.104 | +1.4% | $7.404 | $7.598 | $7.262 | 251 | |
| $7.32 | -0.30 | -3.9% | $7.48 | $7.48 | $7.20 | 443 | |
| $7.62 | +0.004 | +0.1% | $7.692 | $7.83 | $7.60 | 455 | |
| $7.616 | +0.016 | +0.2% | $7.68 | $7.728 | $7.462 | 327 | |
| $7.60 | -0.038 | -0.5% | $7.80 | $7.87 | $7.60 | 89 | |
| $7.638 | -0.082 | -1.1% | $7.60 | $7.80 | $7.60 | 146 | |
| $7.72 | -0.002 | 0.0% | $7.80 | $7.958 | $7.40 | 508 | |
| $7.722 | -0.10 | -1.3% | $8.00 | $8.00 | $7.646 | 285 | |
| $7.822 | -0.044 | -0.6% | $7.94 | $7.94 | $7.668 | 203 |
Splits
2 splits since 2016 · NASDAQ:IMMP · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-20 | Consolidation | |
| 3-for-10 | Consolidation |
- Ticker
- NASDAQ:IMMP
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 18, 2026
Encouraging Disease-Free Survival in Phase II Sarcoma Trial
Latest deck · Aug 20, 2026
Investor Presentation (August 2026)
Investor deck · 30 slides
Latest news
Upcoming Poster Presentations at CTOS and ESMO IO 2026
Nov 4, 2026
Closed $2.69 (-8.8%) on Nov 5, 2026
Immutep Quarterly Activities Report and Appendix 4C
Oct 28, 2026
Closed $3.33 (+0.3%) on Oct 29, 2026
Immutep Receives A$2.16 million French R&D Tax Incentive
Oct 27, 2026
Closed $3.32 (+5.4%) on Oct 28, 2026
Immutep Ltd on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 63 in the last 12 months · 336 in all · newest Nov 18, 2026 · oldest 2016
- Decks
- 112 decks · latest Aug 20, 2026
Where Immutep Ltd is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| ASX:IMM · Home listing | ASX | Australia | AUD |
| NASDAQ:IMMP · This page | NASDAQ | United States | USD |
| gettex:YP1B | gettex | Germany | EUR |
| LS Exchange:A2H81H | LS Exchange | Germany | EUR |
| LS Exchange:A2H8YL | LS Exchange | Germany | EUR |
| OTC:PRRUF | OTC | United States | USD |
| BOATS:IMMP | BOATS | United States | USD |
| Lang & Schwarz:A2H81H | Lang & Schwarz | Germany | EUR |
| gettex:YP1A | gettex | Germany | EUR |
| Frankfurt:YP1B | Frankfurt | Germany | EUR |
| Lang & Schwarz:A2H8YL | Lang & Schwarz | Germany | EUR |
| Stuttgart:YP1A | Stuttgart | Germany | EUR |
| Dusseldorf:YP1B | Dusseldorf | Germany | EUR |
| Hamburg:YP1B | Hamburg | Germany | EUR |
| Stuttgart:YP1B | Stuttgart | Germany | EUR |
| Dusseldorf:YP1A | Dusseldorf | Germany | EUR |
| Frankfurt:YP1A | Frankfurt | Germany | EUR |
| Hamburg:YP1A | Hamburg | Germany | EUR |
| Munich:YP1A | Munich | Germany | EUR |
| Munich:YP1B | Munich | Germany | EUR |
| Tradegate:YP1A | Tradegate | Germany | EUR |
| Tradegate:YP1B | Tradegate | Germany | EUR |
Valuation
EV/sales −2.6× against a median of 3.8×: the lowest of 4 Biotechnology companies shown. Statements: Year to Jun 30, 2026 · price Nov 20, 2026
- Enterprise value
- −$37.66M AUD
- P/E
- Loss
- EV/sales
- −2.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.6×
- Gross margin
- 83.0%
- Operating margin
- −576.2%
- Net margin
- −544.8%
- Debt to equity
- 0.0×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Immutep Ltd · ASX:IMM | US$23.41M | −US$24.93M | n/a | −2.6× | n/a | 0.6× | −544.8% | 0.0× | n/a |
| Original Biomedicals Co Ltd · TPEX:6483 | US$23.81M | US$21.67M | n/a | 1,875× | n/a | 7.1× | n/a | 0.0× | n/a |
| Sernova Biotherapeutics Inc · TSX:SVA | US$23.70M | US$25.46M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| Scynexis, Inc. · NASDAQ:SCYX | US$23.69M | −US$21.66M | n/a | −1.1× | n/a | 0.4× | −53.5% | 0.0× | 1.76 |
| ImmuPharma plc · LSE:IMM | US$23.68M | US$22.77M | n/a | n/a | n/a | 9.9× | n/a | 0.0× | n/a |
| Organoidsciences Ltd. · KRX:476040 | US$23.46M | US$6.52M | n/a | 3.8× | n/a | 1.1× | −814.8% | 0.4× | n/a |
| ABVC BioPharma, Inc. · NASDAQ:ABVC | US$23.37M | US$25.81M | n/a | n/a | n/a | 1.8× | n/a | 0.2× | 1.39 |
| Incannex Healthcare Inc. · NASDAQ:IXHL | US$23.33M | −US$44.85M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.98 |
| Actinogen Medical Limited · ASX:ACW | US$23.08M | US$15.17M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.72M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| Median of the others | US$23.42M | US$18.42M | 3.8× | 1.4× | −434.1% | 0.0× | 0.83 |
Forecasts
Analysts' consensus from EODHD, read Nov 18, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.11 AUD · Analysts' mean
- EPS, year to Jun 2027
- -0.017 · 3 analysts
- Revenue, year to Jun 2027
- 4M · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Marc Voigt | Chief Executive Officer & Executive Director |
| Deanne Miller | Chief Operating Officer, General Counsel & Company Secretary |
| James Flinn | Intellectual Property Director & Legal Counsel |
| David Fang | Finance Director & Assistant Company Secretary |
| Chris Basta | VP, Investor Relations and Corporate Communications |
| Christian Mueller | Chief Development Officer |
| Frédéric Triebel | Chief Scientific Officer & Executive Director |
| Stephan Winckels | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| Russell Howard | Non-Executive Chairman |
| Deanne Miller | Chief Operating Officer, General Counsel & Company Secretary |
| Frédéric Triebel | Chief Scientific Officer & Executive Director |
| Lis Boyce | Non-Executive Director |
| Marc Voigt | Chief Executive Officer & Executive Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Sep 30, 2025 | Dec 3, 2025 | −8.9% |
| Q4 2025 | Aug 28, 2025 | −4.1% |
| Q3 2025 | May 28, 2025 | 0.0% |
| Q2 2025 | Feb 26, 2025 | −1.6% |
| Q1 2025 | Nov 27, 2024 | +3.2% |
| Q4 2024 | Aug 29, 2024 | +6.6% |
| Q3 2024 | May 29, 2024 | 0.0% |
| Q2 2024 | Feb 27, 2024 | +9.2% |
| Q1 2024 | Oct 31, 2023 · Before open | −1.6% |
| Q4 2023 | Aug 30, 2023 · Before open | +1.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Apr 27, 2023 · Before open | 0.0% |
| Q2 2023 | Feb 24, 2023 · After close | −2.0% |
| Q1 2023 | Nov 30, 2022 | −1.4% |
| Q4 2022 | Aug 31, 2022 · After close | −3.5% |
| Q3 2022 | Jun 1, 2022 | 0.0% |
| Q2 2022 | Feb 23, 2022 · Before open | +6.0% |
| Q1 2022 | Dec 1, 2021 | −1.1% |
| Q4 2021 | Aug 30, 2021 | +1.9% |
| Quarter to Mar 31, 2021 | Jun 2, 2021 | 0.0% |
| Quarter to Dec 31, 2020 | Feb 23, 2021 | −10.0% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 30 slides | Aug 20, 2026 |
| Investor Presentation (February 2026) | Investor deck | 39 slides | Feb 20, 2026 |
| Shareholder Meeting (November 2025) | Shareholder meeting | 24 slides | Nov 27, 2025 |
| Investor Presentation (October 2025) | Investor deck | 37 slides | October 2025 |
| Jefferies Global Healthcare Conference 2025 | Conference | 40 slides | Jun 2, 2025 |
| Investor Presentation (February 2025) | Investor deck | 39 slides | Feb 5, 2025 |
| Shareholder Meeting (November 2024) | Shareholder meeting | 16 slides | Nov 22, 2024 |
| European Society for Medical Oncology (ESMO) Congress 2024 | Conference | 15 slides | Sep 15, 2024 |
| Investor Presentation (September 2024) | Investor deck | 63 slides | September 2024 |
| Investor Presentation (August 2024) | Investor deck | 60 slides | Aug 21, 2024 |
Show 50 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2024) | Investor deck | 61 slides | August 2024 |
| Technical Presentation (July 2024) | Technical | 14 slides | Jul 12, 2024 |
| Technical Presentation (July 2024) | Technical | 15 slides | Jul 11, 2024 |
| Corporate Update (June 2024) | Corporate update | 24 slides | Jun 26, 2024 |
| Investor Presentation (June 2024) | Investor deck | 66 slides | Jun 3, 2024 |
| Investor Presentation (March 2024) | Investor deck | 50 slides | March 2024 |
| Investor Presentation (January 2024) | Investor deck | 50 slides | Jan 8, 2024 |
| Shareholder Meeting (October 2023) | Shareholder meeting | 34 slides | Oct 24, 2023 |
| ESMO Congress 2023 | Conference | 25 slides | Oct 22, 2023 |
| ESMO 2023 | Conference | 8 slides | Oct 21, 2023 |
| Investor Presentation (September 2023) | Investor deck | 35 slides | September 2023 |
| Investor Presentation (June 2023) | Investor deck | 39 slides | June 2023 |
| Investor Presentation (May 2023) | Investor deck | 63 slides | May 31, 2023 |
| Investor Presentation (March 2023) | Investor deck | 27 slides | March 2023 |
| Investor Presentation (December 2022) | Investor deck | 33 slides | December 2022 |
| Shareholder Meeting (November 2022) | Shareholder meeting | 22 slides | Nov 23, 2022 |
| Corporate Update (November 2022) | Corporate update | 25 slides | Nov 10, 2022 |
| Investor Presentation (November 2022) | Investor deck | 30 slides | Nov 2, 2022 |
| Non-Small Cell Cancer Drug Development Summit 2022 | Conference | 27 slides | Sep 22, 2022 |
| Conference Presentation (September 2022) | Conference | 27 slides | September 2022 |
| ASCO 2022 | Conference | 27 slides | Jun 6, 2022 |
| Investor Presentation (May 2022) | Investor deck | 35 slides | May 24, 2022 |
| Cowen 42nd Annual Health Care Conference (March 2022) | Conference | 34 slides | March 2022 |
| Shareholder Meeting (November 2021) | Shareholder meeting | 22 slides | Nov 26, 2021 |
| Corporate Update (November 2021) | Corporate update | 32 slides | Nov 17, 2021 |
| Investor Presentation (September 2021) | Investor deck | 46 slides | Sep 27, 2021 |
| Shareholder Meeting (July 2021) | Shareholder meeting | 24 slides | Jul 26, 2021 |
| Non-Small Cell Cancer Drug Development Summit (July 2021) | Conference | 23 slides | Jul 15, 2021 |
| Investor Presentation (June 2021) | Investor deck | 61 slides | Jun 21, 2021 |
| Corporate Update (June 2021) | Corporate update | 38 slides | Jun 10, 2021 |
| Jefferies Virtual Healthcare Conference 2021 | Conference | 33 slides | Jun 4, 2021 |
| Investor Presentation (May 2021) | Investor deck | 48 slides | May 13, 2021 |
| Investor Presentation (February 2021) | Investor deck | 45 slides | Feb 2, 2021 |
| Technical Presentation (December 2020) | Technical | 25 slides | Dec 11, 2020 |
| Investor Presentation (November 2020) | Investor deck | 52 slides | Nov 19, 2020 |
| World Immunotherapy Congress 2020 | Conference | 14 slides | Nov 5, 2020 |
| Shareholder Meeting (October 2020) | Shareholder meeting | 21 slides | Oct 27, 2020 |
| BIO Asia July 2020 | Conference | 17 slides | July 2020 |
| Investor Presentation (April 2020) | Investor deck | 51 slides | Apr 30, 2020 |
| Investor Presentation (April 2020) | Investor deck | 51 slides | Apr 29, 2020 |
This page holds 50 of 112 decks. Open Decks
Financials
Annual, in AUD
Income statement
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.6M | 10.3M | 7.84M | 5.20M | 6.76M | 3.97M | 16.5M | 7.49M | 7.35M | 4.22M |
| Cost of revenue | 2.47M | 61.4M | 41.5M | 2.06M | 2.06M | 2.07M | 22.5M | 16.6M | 9.99M | 1.70M |
| Gross profit | 12.1M | -56.4M | -37.7M | 1.44M | -1.89M | 1.79M | -15.0M | -16.5M | -7.36M | 2.42M |
| Research and development | 76.7M | 49.8M | 31.5M | 28.8M | 25.3M | 12.0M | 15.6M | 13.8M | 9.99M | 7.53M |
| Selling, general and administrative | 9.58M | 8.64M | 8.85M | 8.68M | 7.21M | 6.28M | 6.34M | 6.13M | 7.24M | 4.35M |
| Operating income | -83.9M | -126.4M | -88.1M | -44.9M | -38.4M | -23.5M | -16.0M | -20.4M | -11.7M | -9.35M |
| Depreciation and amortization | 2.47M | 2.39M | 2.26M | 2.06M | 2.06M | 2.07M | 2.08M | 1.88M | 1.81M | 1.70M |
| EBITDA | -81.4M | -124.0M | -85.8M | -42.9M | -36.3M | -21.4M | -13.9M | -18.5M | -9.88M | -7.65M |
| Interest expense | 67.9K | 37.1K | 30.6K | 20.4K | 92.4K | 9.82K | 10.5K | 0 | 0 | 0 |
| Income before tax | -79.3M | -61.4M | -42.7M | -39.9M | -32.2M | -29.9M | -13.5M | -18.3M | -12.7M | -10.1M |
| Income tax | 0 | 0 | 0 | 34 | 33 | 37 | 0 | 1.68K | -737.4K | |
| Net income | -79.3M | -61.4M | -42.7M | -39.9M | -32.2M | -29.9M | -13.5M | -18.3M | -12.7M | -9.37M |
| Earnings per share, basic | -0.05 | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | -0.03 | -5.29 | -4.63 | -0.40 |
| Earnings per share, diluted | -0.04 | -0.04 | -0.04 | -0.04 | -0.05 | -0.03 | -5.29 | -4.63 | -0.40 |
Balance sheet
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 68.9M | 67.4M | 161.8M | 123.4M | 80.0M | 60.6M | 26.3M | 16.6M | 23.5M | 12.2M |
| Short-term investments | 5.20M | 62.3M | 20.1M | 0 | ||||||
| Receivables | 9.62M | 9.87M | 7.35M | 7.95M | 8.37M | 6.12M | 3.29M | 5.19M | 3.43M | 2.19M |
| Inventory | 2 | -1.11M | 465.0K | 1 | 1 | 1 | 642.0K | |||
| Current assets | 80.6M | 149.1M | 191.4M | 135.0M | 90.8M | 68.4M | 31.2M | 23.5M | 28.6M | 15.9M |
| Property, plant and equipment | 63.5K | 63.1K | 83.1K | 37.9K | 40.9K | 49.4K | 53.0K | 26.4K | 24.2K | |
| Goodwill | 110.0K | 110.0K | 110.0K | 110.0K | 110.0K | 110.0K | 110.0K | 110.0K | 110.0K | 110.0K |
| Total assets | 83.3M | 157.0M | 201.6M | 147.4M | 102.2M | 82.0M | 46.6M | 40.5M | 47.0M | 35.0M |
| Accounts payable | 5.89M | 10.6M | 9.56M | 9.02M | 5.75M | 4.78M | 2.93M | 5.06M | 3.66M | 2.59M |
| Current liabilities | 14.2M | 12.8M | 10.5M | 9.77M | 6.41M | 5.34M | 3.36M | 5.30M | 3.85M | 2.63M |
| Long-term debt | 0 | 960.8K | 835.5K | 2.11M | 2.53M | 8.79M | 7.64M | 6.65M | 5.78M | |
| Total debt | 1.05M | 1.63M | 1.59M | 1.44M | 1.84M | 2.90M | 9.05M | 7.64M | 13.3M | 11.6M |
| Total liabilities | 21.7M | 13.3M | 12.1M | 11.0M | 8.09M | 8.76M | 13.3M | 16.2M | 13.5M | 8.43M |
| Shareholders' equity | 61.5M | 143.6M | 189.5M | 136.5M | 94.1M | 73.3M | 33.3M | 24.4M | 33.5M | 26.5M |
| Shares outstanding | 1.47B | 1.46B | 1.20B | 880.2M | 849.0M | 604.3M | 426.9M | 346.8M | 266.8M | 211.9M |
Cash flow
| Line | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -55.5M | -62.0M | -34.8M | -35.4M | -30.2M | -17.6M | -10.8M | -15.3M | -7.78M | -8.51M |
| Capital spending | -92.9K | -45.8K | -29.2K | -82.7K | -22.9K | -15.6K | -19.3K | -41.4K | -11.9K | -6.64K |
| Free cash flow | -55.6M | -62.1M | -34.9M | -35.4M | -30.3M | -17.7M | -10.9M | -15.3M | -7.79M | -8.51M |
| Cash from investing | 56.5M | -38.5M | -21.0M | -82.7K | -22.9K | -15.6K | -19.3K | -41.4K | -11.9K | -6.64K |
| Cash from financing | -214.4K | -525.1K | 95.2M | 76.0M | 50.3M | 52.7M | 20.5M | 8.01M | 18.4M | -8.53K |
| Dividends paid | 0 | 0 | 0 | |||||||
| Share buybacks | 80.1M | 53.0M | 54.6M | 22.0M | 8.79M | 19.7M | 0 | |||
| Change in cash | 1.46M | -101.1M | 39.3M | 40.6M | 20.1M | 35.0M | 9.62M | -7.32M | 10.6M | -8.52M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 19, 2026 | Current report | SEC |
| Encouraging Disease-Free Survival in Phase II Sarcoma Trial | Nov 18, 2026 | Operations update | ASX |
| Immutep Investor Update | Nov 17, 2026 | Other filings | ASX |
| Immutep Expands US Patents for Efti Combination Therapies | Nov 10, 2026 | Other filings | ASX |
| EFTISARC-NEO Survival Data reported in CTOS 2026 Abstract | Nov 10, 2026 | Operations update | ASX |
| 6-K · Report of a foreign issuer | Nov 10, 2026 | Current report | SEC |
| IMP761 Late-Breaking Abstract at ACR shows T-Cell Inhibition | Nov 8, 2026 | Operations update | ASX |
| Upcoming Poster Presentations at CTOS and ESMO IO 2026 | Nov 4, 2026 | Other filings | ASX |
| 6-K · Report of a foreign issuer | Oct 30, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 29, 2026 | Current report | SEC |
Show 200 filings
This page holds 200 of 1,037 filings. Open Filings
Cap table
Built by 6ix from Immutep Ltd’s releases
- Common shares
- 1,473,721,306
- Fully diluted
- 1,473,721,306
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 1,473,721,306 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 1,473,721,306 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Pete Meyers Other companies: Eagle Pharmaceuticals, Inc. (Chief Financial Officer · May 15, 2017 – Jan 23, 2020 · Past); Tetralogic Pharmaceuticals Corp (CFO & Treasurer · Dec 11, 2013 – Mar 27, 2015 · Past) | Director · Since at least Mar 18, 2026 |
| Chris Basta | VP, Investor Relations and Corporate Communications · Since at least Feb 6, 2026 |
| Christian Mueller | Chief Development Officer · Since at least Oct 13, 2025 |
| David Fang | Finance Director & Assistant Company Secretary · Since at least Nov 4, 2026 |
| Deanne Miller | Chief Operating Officer, General Counsel & Company Secretary · Since at least Mar 18, 2026 |
| Elisabeth Amanda Boyce | Director · Since at least Mar 18, 2026 |
| Frédéric Triebel | Chief Scientific Officer & Executive Director · Since at least Mar 18, 2026 |
| James Flinn | Intellectual Property Director & Legal Counsel · Since at least Nov 4, 2026 |
| Lis Boyce | Non-Executive Director · Since at least Nov 5, 2026 |
| Marc Voigt | Chief Executive Officer & Executive Director · Since at least Mar 18, 2026 |
All 12 people
| Person | Seat |
|---|---|
| Russell Howard | Non-Executive Chairman · Since at least Mar 18, 2026 |
| Stephan Winckels | Chief Medical Officer · Since at least Oct 29, 2025 |
Log in to ask 6ix AI your own questions about Immutep Ltd.